Mora P, Aroda V, Asong M, et al
For laboratory and in-vitro research use only
Microdosing, however, seeks and maintains the lowest effective dose
Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, et al
Definition Retatrutide: A 39-amino-acid synthetic peptide that activates the GIP, GLP-1, and glucagon receptors simultaneously
Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
